Skip to main content
Top
Published in: Annals of Intensive Care 1/2021

Open Access 01-12-2021 | Heparin | Research

Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study

Authors: Christophe Leroy, Bruno Pereira, Edouard Soum, Claire Bachelier, Elisabeth Coupez, Laure Calvet, Konstantinos Bachoumas, Claire Dupuis, Bertrand Souweine, Alexandre Lautrette

Published in: Annals of Intensive Care | Issue 1/2021

Login to get access

Abstract

Background

Regional citrate anticoagulation (RCA) is the gold standard of anticoagulation for continuous renal replacement therapy but is rarely used for intermittent hemodialysis (IHD) in ICU. Few studies assessed the safety and efficacy of RCA during IHD in ICU; however, no data are available comparing RCA to heparin anticoagulation, which are commonly used for IHD. The aim of this study was to assess the efficacy and safety of RCA compared to heparin anticoagulation during IHD.

Methods

This retrospective single-center cohort study included consecutive ICU patients treated with either heparin anticoagulation (unfractionated or low-molecular-weight heparin) or RCA for IHD from July to September in 2015 and 2017. RCA was performed with citrate infusion according to blood flow and calcium infusion by diffusive influx from dialysate. Using a propensity score analysis, as the primary endpoint we assessed whether RCA improved efficacy, quantified with Kt/V from the ionic dialysance, compared to heparin anticoagulation. The secondary endpoint was safety. Exploratory analyses were performed on the changes in efficacy and safety between the implementation period (2015) and at long term (2017).

Results

In total, 208 IHD sessions were performed in 56 patients and were compared (124 RCA and 84 heparin coagulation). There was no difference in Kt/V between RCA and heparin (0.95 ± 0.38 vs. 0.89 ± 0.32; p = 0.98). A higher number of circuit clotting (12.9% vs. 2.4%; p = 0.02) and premature interruption resulting from acute high transmembrane pressure (21% vs. 7%; p = 0.02) occurred in the RCA sessions compared to the heparin sessions. In the propensity score-matching analysis, RCA was associated with an increased risk of circuit clotting (absolute differences = 0.10, 95% CI [0.03–0.18]; p = 0.008). There was no difference in efficacy and safety between the two time periods (2015 and 2017).

Conclusion

RCA with calcium infusion by diffusive influx from dialysate for IHD was easy to implement with stable long-term efficacy and safety but did not improve efficacy and could be associated with an increased risk of circuit clotting compared to heparin anticoagulation in non-selected ICU patients. Randomized trials to determine the best anticoagulation for IHD in ICU patients should be conducted in a variety of settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411–23.CrossRef Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411–23.CrossRef
2.
go back to reference Bagshaw SM, Darmon M, Ostermann M, Finkelstein FO, Wald R, Tolwani AJ, et al. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury. Intensive Care Med. 2017;43:841–54.CrossRef Bagshaw SM, Darmon M, Ostermann M, Finkelstein FO, Wald R, Tolwani AJ, et al. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury. Intensive Care Med. 2017;43:841–54.CrossRef
3.
go back to reference Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care Lond Engl. 2007;11:218.CrossRef Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care Lond Engl. 2007;11:218.CrossRef
4.
go back to reference Fiaccadori E, Maggiore U, Clima B, Melfa L, Rotelli C, Borghetti A. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int. 2001;59:1510–9.CrossRef Fiaccadori E, Maggiore U, Clima B, Melfa L, Rotelli C, Borghetti A. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int. 2001;59:1510–9.CrossRef
5.
go back to reference Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976–81.CrossRef Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976–81.CrossRef
6.
go back to reference Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PHJ, Wester JPJ, van der Spoel JI, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37:545–52.CrossRef Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PHJ, Wester JPJ, van der Spoel JI, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37:545–52.CrossRef
7.
go back to reference Monchi M, Berghmans D, Ledoux D, Canivet J-L, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260–5.CrossRef Monchi M, Berghmans D, Ledoux D, Canivet J-L, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260–5.CrossRef
8.
go back to reference Section 5: Dialysis Interventions for Treatment of AKI, Chapter 5.3: Anticoagulation. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl (2011) 2012; 2: 95–100 Section 5: Dialysis Interventions for Treatment of AKI, Chapter 5.3: Anticoagulation. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl (2011) 2012; 2: 95–100
9.
go back to reference Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care Lond Engl. 2012;16:249.CrossRef Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care Lond Engl. 2012;16:249.CrossRef
10.
go back to reference Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care Lond Engl. 2014;18:472.CrossRef Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care Lond Engl. 2014;18:472.CrossRef
11.
go back to reference Gritters M, Grooteman MPC, Schoorl M, Schoorl M, Bartels PCM, Scheffer PG, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2006;21:153–9. Gritters M, Grooteman MPC, Schoorl M, Schoorl M, Bartels PCM, Scheffer PG, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2006;21:153–9.
12.
go back to reference Davenport A. Anticoagulation options for intermittent haemodialysis. Minerva Urol E Nefrol Ital J Urol Nephrol. 2006;58:171–80. Davenport A. Anticoagulation options for intermittent haemodialysis. Minerva Urol E Nefrol Ital J Urol Nephrol. 2006;58:171–80.
13.
go back to reference Faguer S, Saint-Cricq M, Nogier M-B, Labadens I, Lavayssiere L, Kamar N, et al. Heparin-free prolonged intermittent hemodialysis using calcium-free citrate dialysate in critically ill patients. Crit Care Med. 2017;45:1887–92.CrossRef Faguer S, Saint-Cricq M, Nogier M-B, Labadens I, Lavayssiere L, Kamar N, et al. Heparin-free prolonged intermittent hemodialysis using calcium-free citrate dialysate in critically ill patients. Crit Care Med. 2017;45:1887–92.CrossRef
14.
go back to reference Fiaccadori E, Regolisti G, Cademartiri C, Cabassi A, Picetti E, Barbagallo M, et al. Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment. Clin J Am Soc Nephrol CJASN. 2013;8:1670–8.CrossRef Fiaccadori E, Regolisti G, Cademartiri C, Cabassi A, Picetti E, Barbagallo M, et al. Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment. Clin J Am Soc Nephrol CJASN. 2013;8:1670–8.CrossRef
15.
go back to reference Robert T, Bureau C, Lebourg L, Rondeau E, Petitclerc T, Ridel C. A simple and novel technique for regional citrate anticoagulation during intermittent hemodialysis may obviate the need for calcium monitoring. Intensive Care Med. 2017;43:1927–8.CrossRef Robert T, Bureau C, Lebourg L, Rondeau E, Petitclerc T, Ridel C. A simple and novel technique for regional citrate anticoagulation during intermittent hemodialysis may obviate the need for calcium monitoring. Intensive Care Med. 2017;43:1927–8.CrossRef
16.
go back to reference Schneider M, Thomas K, Liefeldt L, Kindgen-Milles D, Peters H, Neumayer H-H, et al. Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study. Clin Nephrol. 2007;68:302–7.CrossRef Schneider M, Thomas K, Liefeldt L, Kindgen-Milles D, Peters H, Neumayer H-H, et al. Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study. Clin Nephrol. 2007;68:302–7.CrossRef
17.
go back to reference Gubensek J, Buturović-Ponikvar J, Skofic N, Ponikvar R. Regional citrate anticoagulation for intermittent predilution online hemofiltration. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2009;13:306–9. Gubensek J, Buturović-Ponikvar J, Skofic N, Ponikvar R. Regional citrate anticoagulation for intermittent predilution online hemofiltration. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2009;13:306–9.
18.
go back to reference Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol CJASN. 2014;9:2173–88.CrossRef Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol CJASN. 2014;9:2173–88.CrossRef
19.
go back to reference Joannes-Boyau O, Velly L, Ichai C. Optimizing continuous renal replacement therapy in the ICU: a team strategy. Curr Opin Crit Care. 2018;24:476–82.CrossRef Joannes-Boyau O, Velly L, Ichai C. Optimizing continuous renal replacement therapy in the ICU: a team strategy. Curr Opin Crit Care. 2018;24:476–82.CrossRef
20.
go back to reference Vinsonneau C, Allain-Launay E, Blayau C, Darmon M, Ducheyron D, Gaillot T, et al. Renal replacement therapy in adult and pediatric intensive care : Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD). Ann Intensive Care. 2015;5:58.CrossRef Vinsonneau C, Allain-Launay E, Blayau C, Darmon M, Ducheyron D, Gaillot T, et al. Renal replacement therapy in adult and pediatric intensive care : Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD). Ann Intensive Care. 2015;5:58.CrossRef
21.
go back to reference Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980;33:27–39.CrossRef Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980;33:27–39.CrossRef
22.
go back to reference Augusto J-F, Lassalle V, Fillatre P, Perrotin D, Meziani F, Schenck-Dhif M, et al. Safety and diagnostic yield of renal biopsy in the intensive care unit. Intensive Care Med. 2012;38:1826–33.CrossRef Augusto J-F, Lassalle V, Fillatre P, Perrotin D, Meziani F, Schenck-Dhif M, et al. Safety and diagnostic yield of renal biopsy in the intensive care unit. Intensive Care Med. 2012;38:1826–33.CrossRef
23.
go back to reference Bitker L, Bayle F, Yonis H, Gobert F, Leray V, Taponnier R, et al. Prevalence and risk factors of hypotension associated with preload-dependence during intermittent hemodialysis in critically ill patients. Crit Care Lond Engl. 2016;20:44.CrossRef Bitker L, Bayle F, Yonis H, Gobert F, Leray V, Taponnier R, et al. Prevalence and risk factors of hypotension associated with preload-dependence during intermittent hemodialysis in critically ill patients. Crit Care Lond Engl. 2016;20:44.CrossRef
24.
go back to reference Schortgen F, Soubrier N, Delclaux C, Thuong M, Girou E, Brun-Buisson C, et al. Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: usefulness of practice guidelines. Am J Respir Crit Care Med. 2000;162:197–202.CrossRef Schortgen F, Soubrier N, Delclaux C, Thuong M, Girou E, Brun-Buisson C, et al. Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: usefulness of practice guidelines. Am J Respir Crit Care Med. 2000;162:197–202.CrossRef
25.
go back to reference Souweine B, Lautrette A, Gruson D, Canet E, Klouche K, Argaud L, et al. Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial. Am J Respir Crit Care Med. 2015;191:1024–32.CrossRef Souweine B, Lautrette A, Gruson D, Canet E, Klouche K, Argaud L, et al. Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial. Am J Respir Crit Care Med. 2015;191:1024–32.CrossRef
26.
go back to reference VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20. VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20.
27.
go back to reference Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol. 2001;54:343–9.CrossRef Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol. 2001;54:343–9.CrossRef
28.
go back to reference Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002;346:305–10.CrossRef Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002;346:305–10.CrossRef
29.
go back to reference Ridel C, Osman D, Mercadal L, Anguel N, Petitclerc T, Richard C, et al. Ionic dialysance: a new valid parameter for quantification of dialysis efficiency in acute renal failure? Intensive Care Med. 2007;33:460–5.CrossRef Ridel C, Osman D, Mercadal L, Anguel N, Petitclerc T, Richard C, et al. Ionic dialysance: a new valid parameter for quantification of dialysis efficiency in acute renal failure? Intensive Care Med. 2007;33:460–5.CrossRef
30.
go back to reference Lindsay RM, Bene B, Goux N, Heidenheim AP, Landgren C, Sternby J. Relationship between effective ionic dialysance and in vivo urea clearance during hemodialysis. Am J Kidney Dis Off J Natl Kidney Found. 2001;38:565–74.CrossRef Lindsay RM, Bene B, Goux N, Heidenheim AP, Landgren C, Sternby J. Relationship between effective ionic dialysance and in vivo urea clearance during hemodialysis. Am J Kidney Dis Off J Natl Kidney Found. 2001;38:565–74.CrossRef
31.
go back to reference Davenport A. What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol. 2011;7:499–508.CrossRef Davenport A. What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol. 2011;7:499–508.CrossRef
Metadata
Title
Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
Authors
Christophe Leroy
Bruno Pereira
Edouard Soum
Claire Bachelier
Elisabeth Coupez
Laure Calvet
Konstantinos Bachoumas
Claire Dupuis
Bertrand Souweine
Alexandre Lautrette
Publication date
01-12-2021
Publisher
Springer International Publishing
Keyword
Heparin
Published in
Annals of Intensive Care / Issue 1/2021
Electronic ISSN: 2110-5820
DOI
https://doi.org/10.1186/s13613-021-00803-x

Other articles of this Issue 1/2021

Annals of Intensive Care 1/2021 Go to the issue